ArticleJournal of controlled release : official journal of the Controlled Release Society2011
High-affinity peptide against MT1-MMP for in vivo tumor imaging.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 66 citations in OpenAlex.
- Comparison of 5-aminolevulinic acid and MMP-14 targeted peptide probes in preclinical models of GBM.Theranostics · 2025Article
- Analysis of Compositional Bias in a Commercial Phage Display Peptide Library by Next-Generation Sequencing.Viruses · 2022Article
- Development of anti-membrane type 1-matrix metalloproteinase nanobodies as immunoPET probes for triple negative breast cancer imaging.Frontiers in medicine · 2022Article
- Qualitative and Quantitative Analysis of Tumor Cell Invasion Using Au Clusters.Nanomaterials (Basel, Switzerland) · 2021Article
- Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.European journal of nuclear medicine and molecular imaging · 2020Article
- MT1-MMP activatable fluorogenic probes with enhanced specificity via high-affinity peptide conjugation for tumor imaging.Biomaterials science · 2020Article
- iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.Journal of oncology · 2019Review
- Optimization of a MT1-MMP-targeting Peptide and Its Application in Near-infrared Fluorescence Tumor Imaging.Scientific reports · 2018Article
- MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management.Contrast media & molecular imaging · 2018Article
- Phosphoramidate-based peptidomimetic inhibitors of membrane type-1 matrix metalloproteinase.Journal of enzyme inhibition and medicinal chemistry · 2016Article
- Article
- Development of Radiolabeled Membrane Type-1 Matrix Metalloproteinase Activatable Cell Penetrating Peptide Imaging Probes.Molecules (Basel, Switzerland) · 2015Article
- SORTCERY-A High-Throughput Method to Affinity Rank Peptide Ligands.Journal of molecular biology · 2015Article
- Development of a Radiolabeled Peptide-Based Probe Targeting MT1-MMP for Breast Cancer Detection.PloS one · 2015Article
- Article
- Visualization of protease activity in vivo using an activatable photo-acoustic imaging probe based on CuS nanoparticles.Theranostics · 2014Article
- Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).Molecular pharmaceutics · 2013Article
- Miniaturized antibodies for imaging membrane type-1 matrix metalloproteinase in cancers.Cancer science · 2013Article
- Nanoparticles for Improving Cancer Diagnosis.Materials science & engineering. R, Reports : a review journal · 2013Article
- PET imaging of inflammation biomarkers.Theranostics · 2013Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 5 institutions in 2 countries.
Funding
Abstract
Membrane type-1 matrix metalloproteinase (MT1-MMP) is a key member of the matrix metalloproteinase (MMP) family. It participates in pericellular proteolysis of extracellular matrix (ECM) macromolecules and is essential for many biological and pathological processes, such as tumor development, angiogenesis and metastasis. A ligand that specifically binds to MT1-MMP may facilitate the labeling of this molecule, allow imaging at the cellular and organism levels, and provide a means for targeted drug delivery specific to MT1-MMP. A non-substrate MT1-MMP binding peptide was identified by screening a Ph.D.-12™ phage display peptide library and conjugated with near-infrared fluorescent (NIRF) dye Cy5.5 for tumor imaging. Peptide HWKHLHNTKTFL (denoted as MT1-AF7p) showed high MT1-MMP binding affinity. Computer modeling verified that MT1-AF7p binds to the MT-loop region of MT1-MMP and interacts with MT1-MMP through hydrogen bonding and hydrophobic interactions. MDA-MB-435 xenografts with high MT1-MMP expression had significantly higher tumor accumulation and better tumor contrast than the low MT1-MMP expressing A549 xenografts after intravenous injection of Cy5.5-MT1-AF7p. Using NIRF imaging, we have demonstrated specific targeting of MT1-AF7p to MT1-MMP-expressing tumors. Thus, MT1-AF7p is an important tool for noninvasive monitoring of MT1-MMP expression in tumors, and it shows great potential as an imaging agent for MT1-MMP-positive tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.